Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP, from the Barts Cancer Institute, London, UK, discusses the results of their groundbreaking Phase II PAKT trial (NCT02423603) investigating the value of adding the AKT inhibitor capivasertib to paclitaxel for the first-line treatment of patients with metastatic triple-negative breast cancer (TNBC). Prof. Schmid talks about the changes in progression-free and overall survival observed in both the entire patient cohort and in a subset of patients with mutations that promote activation of the PI3K/AKT/mTOR pathway. He then compares these results with those that were observed in the similar Phase II LOTUS trial (NCT02162719) and talks about the Phase III studies that will follow these trials.
